Loading…
Back To Schedule
Tuesday, September 20 • 10:00am - 10:30am
Case Study: Bringing Back Rofecoxib/Vioxx for Non-Opioid Pain Relief: The Inside Story

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Eighteen years after Merck voluntarily pulled rofecoxib (Vioxx) from the market because of concerns that it increased heart attack and stroke risks, Massachusetts-based Tremeau Pharmaceuticals is expanding its development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
CEO Brad Sippy presents an inside look at how he is navigating the challenges of redeveloping this once broadly-marketed into a treatment for a select patient groups. The interactive case study discusses key learnings in establishing the unmet need, making the case for a pivotal trial with regulators and finding the right investors.

Speakers
avatar for Brad Sippy

Brad Sippy

Chief Executive Officer, Tremeau Pharmaceuticals
Brad Sippy founded Tremeau Pharmaceuticals in July 2016. He brings over 25 years of pharmaceutical industry experience across multiple therapeutic areas. He most recently served as Vice President and Head of U.S. Marketing for Sunovion Pharmaceuticals, where he oversaw all in-line... Read More →

Tuesday September 20, 2022 10:00am - 10:30am EDT
  General Session